CMR and adverse clinical outcomes in peripartum cardiomyopathy

CMR and adverse clinical outcomes in peripartum cardiomyopathy

Background: Peripartum cardiomyopathy (PPCM) is associated with significant morbidity and mortality. Recent studies show recovery of left ventricular ejection fraction (LVEF) can still be associated with longitudinal adverse clinical outcomes. Cardiac MRI (CMR) may yield additional prognostic parame...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnes Koczo, Deeksha Acharya, Benay Ozbay, Rami Alharethi, Michael M. Givertz, Uri Elkayam, Erik B. Schelbert, Dennis M. McNamara, Timothy C. Wong
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:American Heart Journal Plus
Subjects:
Peripartum cardiomyopathy
Cardiac MRI
Diffuse interstitial fibrosis
Adverse outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2666602224001277
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Peripartum cardiomyopathy (PPCM) is associated with significant morbidity and mortality. Recent studies show recovery of left ventricular ejection fraction (LVEF) can still be associated with longitudinal adverse clinical outcomes. Cardiac MRI (CMR) may yield additional prognostic parameters of serious adverse outcomes (SAE) beyond LVEF. Methods: Individuals with PPCM and CMR within 3 months of diagnosis were analyzed from the Investigations in Pregnancy Associated Cardiomyopathy (IPAC) trial and our institution from 2010-present. Indexed left ventricular (LV) mass, ventricular volumes, cardiac output, global longitudinal strain (GLS), extracellular cellular volume (ECV) as well as epicardial fat volume (EFV) were analyzed. SAEs included left ventricular assist device (LVAD), heart transplant and death. CMR parameters were compared between SAE and no SAEs groups by non-parametric techniques. Results: Among 51 individuals with mean age of 31 years at diagnosis, 6/51 (12 %) experienced 11 adverse outcomes. EF at time of CMR (15.0 vs 37.3 %, p < 0.001), peak LV GLS (−4.1 % vs −10.0, p = 0.002) ECV (43.6 vs 28.2, p = 0.02) and stroke volume differed significantly among groups. In univariate regression analysis, worse LVEF, lower peak GLS and greater LVESVi were predictive of adverse outcomes. Conclusion: Prior studies found baseline LVEF by echo is a predictor of serious adverse outcomes. CMR identified significantly different baseline LVESVi peak LV GLS and ECV among PPCM with SAEs vs no SAEs. If confirmed in larger studies, diffuse myocardial fibrosis may represent a therapeutic target in PPCM.
ISSN:2666-6022

Similar Items